Products
Romilkimab Biosimilar Bispecific Dual-Variable-Domain Antibody (IL-13 × IL-4) for Research
Cat No.: GMP-Bios-ab-492
Pre-Made Romilkimab biosimilar, Bispecific Dual Variable Domain IG, Anti-IL13;IL4 Antibody: Anti-IL-13/P600;BCGF-1/BCGF1/BSF-1/BSF1/IL-4 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Romilkimab (SAR156597), however, “is an engineered, humanised, bispecific immunoglobulin-G4 antibody that binds and neutralizes IL-4/IL-13 making it ideal for exploration in fibrosis,” the researchers explain.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-ab-492-1mg | 1mg | |
| GMP-Bios-ab-492-10mg | 10mg | |
| GMP-Bios-ab-492-100mg | 100mg | |
| GMP-Bios-ab-492-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Romilkimab biosimilar, Bispecific Dual Variable Domain IG, Anti-IL13;IL4 Antibody: Anti-IL-13/P600;BCGF-1/BCGF1/BSF-1/BSF1/IL-4 therapeutic antibody |
| INN Name | Romilkimab |
| Target | IL13;IL4 |
| Format | Bispecific Dual Variable Domain IG |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa;Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2017 |
| Year Recommended | 2018 |
| Companies | Sanofi |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Idiopathic pulmonary fibrosis |
| Development Tech | na |
About target - IL13
1. Protein Interleukin-13 receptor subunit alpha-1
2. Gene IL13RA1
3. Organism Homo sapiens (Human)
Function
Binds with low affinity to interleukin-13 (IL13). Together with IL4RA can form a functional receptor for IL13. Also serves as an alternate accessory protein to the common cytokine receptor gamma chain for interleukin-4 (IL4) signaling, but cannot replace the function of IL2RG in allowing enhanced interleukin-2 (IL2) binding activity.
